Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 188Dermatologic 88Tumor-Agnostic 77Gastrointestinal 45Thoracic 32Gynecologic 23Genitourinary 16Sarcoma 11CNS 6Breast 6Lymphoid 5Endocrine 3Plasma cell 2Other solid neoplasm 2Myeloid 2Other neoplasm 1Other hematologic neoplasm 1Other 1NET 1Classical hematology 1

Conditions

Precancerous Conditions 138Lymphoma 35Leukemia 34Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 32Neoplasms, Plasma Cell 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Monoclonal Gammopathy of Undetermined Significance 29Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 29Lymphoma, Large-Cell, Immunoblastic 29Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 29Burkitt Lymphoma 28Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell, Marginal Zone 27Hodgkin Disease 27Myelodysplastic Syndromes 26Immunoglobulin Light-chain Amyloidosis 26Myeloproliferative Disorders 25Lymphoma, T-Cell, Cutaneous 25Immunoblastic Lymphadenopathy 25Waldenstrom Macroglobulinemia 24Lymphoma, Large-Cell, Anaplastic 24Leukemia, Myeloid, Acute 24Uterine Cervical Neoplasms 22Primary Myelofibrosis 22Leukemia, Large Granular Lymphocytic 22Leukemia, Hairy Cell 22Thrombocythemia, Essential 21

Interventions

Imiquimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Squamous Cell × Other neoplasm × Clear all
NCT00175643 2006-05-09

Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

University of British Columbia

Phase 3 Completed
20 enrolled
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡